By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Epigenomics today reported that its full-year 2010 revenues declined 58 percent, due to non-recurring revenue in 2009 tied to R&D support for partners.

The Berlin, Germany-based firm said that its 2010 revenues were €1.8 million ($2.6 million), down from €4.3 million in 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.